[
  {
    "title": "Financial Highlights",
    "subtitle": "Fourth Quarter Results",
    "markdown": "| | 2024 | 2023 | Change (%) | Organic CC Growth (%) |\n| --- | --- | --- | --- | --- |\n| Pet Health | $439 | $416 | 6% | 6% |\n| Farm Animal | $570 | $610 | (7)% | 2% |\n| Cattle | $253 | $249 | 2% | 3% |\n| Poultry | $213 | $220 | (3)% | (2)% |\n| Swine | $104 | $98 | 6% | 7% |\n| Aqua | $ | $43 | (100)% |  |\n| Contract Manufacturing and Other | $11 | $9 | 22% |  |\n| Total Revenue | $1,020 | $1,035 | (1)% | 4% |\n| Reported Net Loss | $(8) | $(141) |  |  |\n| Adjusted EBITDA | $177 | $165 | 7% |  |\n| Reported EPS | $(0.02) | $(0.29) |  |  |\n| Adjusted EPS | $0.14 | $0.08 | 75% |  |",
    "footnotes": [
      "(1) Organic CC Growth represents organic growth on a constant currency basis",
      "(2) Contract Manufacturing and Other includes other revenue streams"
    ],
    "units": "(dollars in millions, except per share amounts)",
    "page": 3,
    "bbox": [
      23.5,
      338.4,
      569.8,
      533.1
    ],
    "som_region": [
      0.03839224148419947,
      0.3268438782354798,
      0.9310565025977838,
      0.5727286290640783
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 99.24,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Full Year Results",
    "subtitle": "(dollars in millions, except per share amounts)",
    "markdown": "| | 2024 | 2023 | Change (%) | Organic CC Growth (%) |\n| --- | --- | --- | --- | --- |\n| Pet Health | $2,143 | $2,104 | 2% | 2% |\n| Farm Animal | $2,250 | $2,271 | (1)% | 4% |\n| Cattle | $1,007 | $949 | 6% | 7% |\n| Poultry | $796 | $765 | 4% | 5% |\n| Swine | $366 | $382 | (4)% | (3)% |\n| Aqua | $81 | $175 | (54)% |  |\n| Contract Manufacturing and Other | $46 | $42 | 10% |  |\n| Total Revenue | $4,439 | $4,417 | % | 3% |\n| Reported Net Income (loss) | $338 | $(1,231) |  |  |\n| Adjusted EBITDA | $910 | $979 | (7)% |  |\n| Reported EPS | $0.68 | $(2.50) |  |  |\n| Adjusted EPS | $0.91 | $0.89 | 2% |  |",
    "footnotes": [
      "Organic CC Growth = Representing revenue growth excluding revenue from the aqua business, which the company divested July 9, 2024, and the impact of foreign exchange rates.",
      "Primarily represents revenue from arrangements in which the company manufactures products on behalf of a third party and royalty revenue.",
      "Numbers may not add due to rounding."
    ],
    "units": "",
    "page": 3,
    "bbox": [
      22.5,
      67.3,
      589.5,
      323.1
    ],
    "som_region": [
      0.03676470588235294,
      0.5919841419566761,
      0.9631724638097426,
      0.9149813411211727
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 96.91,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "2025 Full Year",
    "subtitle": "",
    "markdown": "| Metric | Low | High |\n| --- | --- | --- |\n| Revenue | $4,445 | $4,510 |\n| Reported Net (Loss) Income | $(25) | $7 |\n| Adjusted EBITDA | $830 | $870 |\n| Reported (Loss) Income per Share | $(0.05) | $0.01 |\n| Adjusted Earnings per Share | $0.80 | $0.86 |",
    "footnotes": [
      "The company anticipates a headwind to revenue of approximately $110 million from the unfavorable impact of foreign exchange rates compared to prior year and since the November earnings call. Excluding the unfavorable impact of foreign"
    ],
    "units": "(dollars in millions, except per share amounts)",
    "page": 6,
    "bbox": [
      22.5,
      446.4,
      589.5,
      582.1
    ],
    "som_region": [
      0.03676470588235294,
      0.26507778360386086,
      0.963162091822406,
      0.43637038722182764
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 94.9,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "2025 First Quarter",
    "subtitle": "",
    "markdown": "| Guidance | Low | to | High |\n| --- | --- | --- | --- |\n| Revenue | $1,155 | to | $1,180 |\n| Reported Net Income | $13 | to | $41 |\n| Adjusted EBITDA | $240 | to | $260 |\n| Reported Income per Share | $0.03 | to | $0.08 |\n| Adjusted Earnings per Share | $0.29 | to | $0.34 |",
    "footnotes": [
      "In the first quarter, the company expects a headwind to revenue of approximately $40 million from the unfavorable impact of foreign exchange rates compared to prior year. Excluding the unfavorable impact of foreign exchange rates and the aqua"
    ],
    "units": "(dollars in millions, except per share amounts)",
    "page": 6,
    "bbox": [
      22.5,
      144.2,
      589.5,
      279.8
    ],
    "som_region": [
      0.03676470588235294,
      0.6466902145231613,
      0.9631875231375102,
      0.8179834539240056
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 94.73,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Elanco Animal Health Incorporated Unaudited Consolidated Statements of Operations",
    "subtitle": "",
    "markdown": "| | Three Months Ended December 31, 2024 | Three Months Ended December 31, 2023 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |\n| --- | --- | --- | --- | --- |\n| Revenue | $ 1,020 | $ 1,035 | $ 4,439 | $ 4,417 |\n| Costs, expenses, and other: | | | | |\n| Cost of sales | 501 | 516 | 2,003 | 1,931 |\n| Research and development | 81 | 79 | 344 | 327 |\n| Marketing, selling and administrative | 300 | 292 | 1,314 | 1,285 |\n| Amortization of intangible assets | 130 | 138 | 527 | 548 |\n| Asset impairment, restructuring, and other special charges | 7 | 36 | 150 | 127 |\n| Goodwill impairment | | | | 1,042 |\n| Gain on divestiture | | | (640) | |\n| Interest expense, net of capitalized interest | 46 | 67 | 235 | 277 |\n| Other expense, net | 6 | 34 | 18 | 75 |\n| (Loss) income before income taxes | $ (51) | $ (127) | $ 488 | $ (1,195) |\n| Income tax (benefit) expense | (43) | 14 | 150 | 36 |\n| Net (loss) income | $ (8) | $ (141) | $ 338 | $ (1,231) |\n| (Loss) earnings per share: | | | | |\n| Basic | $ (0.02) | $ (0.29) | $ 0.68 | $ (2.50) |\n| Diluted | $ (0.02) | $ (0.29) | $ 0.68 | $ (2.50) |\n| Weighted average shares outstanding: | | | | |\n| Basic | 494.4 | 492.8 | 494.0 | 492.3 |\n| Diluted | 494.4 | 492.8 | 497.3 | 492.3 |",
    "footnotes": [],
    "units": "(Dollars and shares in millions, except per share data)",
    "page": 12,
    "bbox": [
      30.8,
      368.4,
      581.2,
      714.8
    ],
    "som_region": [
      0.05032111772524765,
      0.097471555074056,
      0.9496166752833946,
      0.5348515366062974
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 96.45,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Elanco Animal Health Incorporated Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information",
    "subtitle": "(Unaudited)",
    "markdown": "| | Three months ended December 31, 2024 | | | Three months ended December 31, 2023 | | |\n| --- | --- | --- | --- | --- | --- | --- |\n| | GAAP Reported | Adjusted Items (b) | Non-GAAP (a) | GAAP Reported | Adjusted Items (b) | Non-GAAP (a) |\n| Amortization of intangible assets | $ 130 | $ 130 | $ | $ 138 | $ 138 | $ |\n| Asset impairment, restructuring and other special charges (1) | 7 | 7 | | 36 | 36 | |\n| Other expense, net (2) | 6 | 11 | (5) | 34 | 18 | 16 |\n| (Loss) income before taxes | (51) | 149 | 98 | (127) | 192 | 65 |\n| Income tax (benefit) expense (3) | (43) | (69) | 26 | 14 | (12) | 26 |\n| Net (loss) income | $ (8) | $ 80 | $ 72 | $ (141) | $ 180 | $ 39 |\n| (Loss) earnings per share: | | | | | | |\n| basic | $ (0.02) | $ 0.17 | $ 0.15 | $ (0.29) | $ 0.37 | $ 0.08 |\n| diluted | $ (0.02) | $ 0.16 | $ 0.14 | $ (0.29) | $ 0.37 | $ 0.08 |\n| Adjusted weighted average shares outstanding: | | | | | | |\n| basic | 494.4 | 494.4 | 494.4 | 492.8 | 492.8 | 492.8 |\n| diluted (4) | 494.4 | 498.4 | 498.4 | 492.8 | 494.9 | 494.9 |\n| Numbers may not add due to rounding. | | | | | | |",
    "footnotes": [
      "We define adjusted gross profit as total revenue less adjusted cost of sales and adjusted gross margin as adjusted gross profit divided by total revenue.",
      "We define adjusted net income as net income (loss) excluding amortization of intangible assets, purchase accounting adjustments to inventory, acquisition and divestiture-related charges, including integration and separation costs, severance, goodwill and other asset impairments, gain on sale of assets and related costs, facility exit costs, tax valuation allowances and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations adjusted for income tax expense associated with the excluded financial items.",
      "We define adjusted EBITDA as net income (loss) adjusted for interest expense (income), which includes debt extinguishment losses, income tax expense (benefit) and depreciation and amortization, further adjusted to exclude purchase accounting adjustments to inventory, acquisition and divestiture-related charges, including integration and separation costs, severance, goodwill and other asset impairments, gains on sale of assets and related costs, facility exit costs and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations.",
      "We define adjusted EPS as adjusted net income (loss) divided by the number of weighted-average shares outstanding for the periods ended December 31, 2024 and 2023.",
      "We define gross debt as the sum of the current portion of long-term debt and long-term debt excluding unamortized debt issuance costs. We define net debt as gross debt less cash and cash equivalents on the balance sheet. We define the net leverage ratio as net debt divided by trailing twelve month adjusted EBITDA. This calculation does not include Term Loan B covenant-related adjustments that reduce this leverage ratio."
    ],
    "units": "(Dollars and shares in millions, except per share data)",
    "page": 13,
    "bbox": [
      22.5,
      145.7,
      589.5,
      714.8
    ],
    "som_region": [
      0.03676470588235294,
      0.09747093855732619,
      0.9631968978183721,
      0.8160898227884312
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 86.71,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Three Months Ended December 31,",
    "subtitle": "",
    "markdown": "| | Three Months Ended December 31, 2024 | Three Months Ended December 31, 2023 |\n| --- | --- | --- |\n| As reported diluted EPS | $ (0.02) | $ (0.29) |\n| Amortization of intangible assets | 0.26 | 0.28 |\n| Asset impairment, restructuring and other special charges | 0.02 | 0.07 |\n| Other expense, net | 0.02 | 0.04 |\n| Subtotal | 0.30 | 0.39 |\n| Tax impact of adjustments (1) | (0.14) | (0.02) |\n| Total adjustments to diluted EPS | $ 0.16 | $ 0.37 |\n| Adjusted diluted EPS (2) | $ 0.14 | $ 0.08 |",
    "footnotes": [
      "Numbers may not add due to rounding.",
      "(1) 2024 and 2023 included favorable adjustments relating to increases in the valuation allowance recorded against our deferred tax assets of $0.16 per share in each period.",
      "(2) Adjusted diluted EPS is calculated as the sum of as reported diluted EPS and total adjustments to diluted EPS."
    ],
    "units": "",
    "page": 15,
    "bbox": [
      22.5,
      147.2,
      589.5,
      364.3
    ],
    "som_region": [
      0.03676470588235294,
      0.5400833746399543,
      0.9631730621936274,
      0.8141958833944918
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 96.2,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "The following is a reconciliation of GAAP Reported for the year ended December 31, 2024 and 2023, to Selected Non-GAAP Adjusted information:",
    "subtitle": "",
    "markdown": "| | Twelve months ended December 31, 2024 | | | Twelve months ended December 31, 2023 | | |\n| --- | --- | --- | --- | --- | --- | --- |\n| | GAAP Reported | Adjusted Items (b) | Non-GAAP (a) | GAAP Reported | Adjusted Items (b) | Non-GAAP (a) |\n| Cost of sales | $ 2,003 | $ | $ 2,003 | $ 1,931 | $ 2 | $ 1,929 |\n| Amortization of intangible assets | 527 | 527 | | 548 | 548 | |\n| Asset impairment, restructuring and other special charges (1) | 150 | 150 | | 127 | 127 | |\n| Goodwill impairment | | | | 1,042 | 1,042 | |\n| Gain on divestiture | (640) | (640) | | | | |\n| Interest expense, net of capitalized interest (2) | 235 | 12 | 223 | 277 | | 277 |\n| Other expense, net (3) | 18 | 15 | 3 | 75 | 42 | 33 |\n| Income (loss) before taxes | 488 | 64 | 552 | (1,195) | 1,761 | 566 |\n| Income tax expense (4) | 150 | 50 | 100 | 36 | (91) | 127 |\n| Net income (loss) | $ 338 | $ 114 | $ 452 | $ (1,231) | $ 1,670 | $ 439 |\n| Earnings (loss) per share: | | | | | | |\n| basic | $ 0.68 | $ 0.23 | $ 0.91 | $ (2.50) | $ 3.39 | $ 0.89 |\n| diluted | $ 0.68 | $ 0.23 | $ 0.91 | $ (2.50) | $ 3.39 | $ 0.89 |\n| Adjusted weighted average shares outstanding: | | | | | | |\n| basic | 494.0 | 494.0 | 494.0 | 492.3 | 492.3 | 492.3 |\n| diluted (5) | 497.3 | 497.3 | 497.3 | 492.3 | 493.7 | 493.7 |\n| Numbers may not add due to rounding. | | | | | | |",
    "footnotes": [],
    "units": "",
    "page": 16,
    "bbox": [
      22.5,
      392.4,
      589.5,
      720.8
    ],
    "som_region": [
      0.03676470588235294,
      0.08989518098156862,
      0.9631728627323325,
      0.5045491228199969
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 96.52,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Twelve Months Ended December 31,",
    "subtitle": "",
    "markdown": "| | Twelve Months Ended December 31, 2024 | Twelve Months Ended December 31, 2023 |\n| --- | --- | --- |\n| As reported diluted EPS | $ 0.68 | $ (2.50) |\n| Amortization of intangible assets | 1.06 | 1.11 |\n| Asset impairment, restructuring and other special charges | 0.30 | 0.26 |\n| Goodwill impairment | | 2.11 |\n| Gain on divestiture | (1.29) | |\n| Interest expense, net of capitalized interest | 0.03 | |\n| Other expense, net | 0.03 | 0.09 |\n| Subtotal | $ 0.13 | $ 3.57 |\n| Tax impact of adjustments (1) | 0.10 | (0.18) |\n| Total adjustments to diluted EPS | $ 0.23 | $ 3.39 |\n| Adjusted diluted EPS (2) | $ 0.91 | $ 0.89 |\n| Numbers may not add due to rounding. | | |",
    "footnotes": [
      "(1) 2023 includes a favorable adjustment relating to the increase in the valuation allowance recorded against our deferred tax assets.",
      "(2)"
    ],
    "units": "",
    "page": 17,
    "bbox": [
      22.5,
      315.9,
      569.0,
      526.2
    ],
    "som_region": [
      0.03676470588235294,
      0.33554655132871686,
      0.9297326779833026,
      0.6011375658439867
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 98.29,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Three Months Ended December 31 and Twelve Months Ended December 31 - EBITDA Reconciliation",
    "subtitle": "",
    "markdown": "| | Three Months Ended December 31, 2024 | Three Months Ended December 31, 2023 | Twelve Months Ended December 31, 2024 | Twelve Months Ended December 31, 2023 |\n| --- | --- | --- | --- | --- |\n| Reported net (loss) income | $ (8) | $ (141) | $ 338 | $ (1,231) |\n| Net interest expense | 46 | 67 | 235 | 277 |\n| Income tax expense (benefit) | (43) | 14 | 150 | 36 |\n| Depreciation and amortization | 164 | 171 | 662 | 694 |\n| EBITDA | $ 159 | $ 111 | $ 1,385 | $ (224) |\n| Non-GAAP Adjustments: | | | | |\n| Cost of sales | $ | $ | $ | $ 2 |\n| Asset impairment, restructuring and other special charges | 7 | 36 | 150 | 127 |\n| Goodwill impairment | | | | 1,042 |\n| Gain on divestiture | | | (640) | |\n| Other expense, net | 11 | 18 | 15 | 42 |\n| Accelerated depreciation and amortization(1) | | | | (10) |\n| Adjusted EBITDA | $ 177 | $ 165 | $ 910 | $ 979 |\n| Adjusted EBITDA Margin | 17.4% | 15.9% | 20.5% | 22.2% |",
    "footnotes": [
      "Numbers may not add due to rounding.",
      "(1) Represents depreciation and amortization of certain assets that was accelerated during the period presented. These"
    ],
    "units": "",
    "page": 18,
    "bbox": [
      22.5,
      369.1,
      586.8,
      629.0
    ],
    "som_region": [
      0.03676470588235294,
      0.20581665424385456,
      0.9588969112221711,
      0.5339039503925979
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 97.36,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "The following is a reconciliation of gross debt to net debt as of December 31, 2024:",
    "subtitle": "",
    "markdown": "| | |\n| --- | --- |\n| Long-term debt | $ 4,277 |\n| Current portion of long-term debt | 44 |\n| Less: Unamortized debt issuance costs | (28) |\n| Total gross debt | 4,349 |\n| Less: Cash and cash equivalents | 468 |\n| Net Debt | $ 3,881 |",
    "footnotes": [],
    "units": "",
    "page": 18,
    "bbox": [
      22.5,
      195.9,
      588.0,
      322.6
    ],
    "som_region": [
      0.03676470588235294,
      0.5927151381367385,
      0.9607039308236315,
      0.7526453191583806
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 99.48,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Reconciliation of 2025 full year reported EPS guidance to 2025 adjusted EPS guidance is as follows:",
    "subtitle": "",
    "markdown": "| | Full Year 2025 Guidance | |\n| --- | --- | --- |\n| Reported (loss) income per share | $(0.05) to $0.01 | |\n| Amortization of intangible assets | Approx. $1.02 | |\n| Asset Impairment, restructuring and other special charges | $0.05 to $0.03 | |\n| Other expense, net | $0.03 to $0.04 | |\n| Subtotal | $1.10 to $1.09 | |\n| Tax impact of adjustments | $(0.25) to $(0.24) | |\n| Total adjustments to EPS | $0.85 to $0.85 | |\n| Adjusted earnings per share | $0.80 to $0.86 | |",
    "footnotes": [
      "(1)"
    ],
    "units": "",
    "page": 20,
    "bbox": [
      34.7,
      532.6,
      577.6,
      646.6
    ],
    "som_region": [
      0.0567738152796926,
      0.18364147224811594,
      0.9438121521395016,
      0.3274731684212733
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 97.17,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "Reconciliation of 2025 reported net (loss) income to 2025 adjusted EBITDA guidance is as follows:",
    "subtitle": "",
    "markdown": "| | Full Year 2025 Guidance |\n| --- | --- |\n| Reported net (loss) income | $(25) to $7 |\n| Net interest expense | Approx. $200 |\n| Income tax expense (benefit) | $(18) to $(6) |\n| Depreciation and amortization | Approx. $640 |\n| EBITDA | $792 to $842 |\n| Non-GAAP Adjustments |  |\n| Asset impairment, restructuring and other special charges | Approx. $20 |\n| Other expense, net | Approx. $15 |\n| Adjusted EBITDA | $830 to $870 |\n| Adjusted EBITDA margin | 18.7% to 19.3% |",
    "footnotes": [
      "Numbers may not add due to rounding."
    ],
    "units": "$ millions",
    "page": 20,
    "bbox": [
      22.5,
      279.9,
      576.0,
      456.8
    ],
    "som_region": [
      0.03676470588235294,
      0.4232149605799203,
      0.9411089529398999,
      0.6465884121981534
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 100.0,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "First Quarter 2025 Guidance",
    "subtitle": "Reconciliation of 2025 first quarter reported EPS guidance to 2025 first quarter adjusted EPS guidance",
    "markdown": "| | First Quarter 2025 Guidance | |\n| --- | --- | --- |\n| | Low | High |\n| Reported income per share | $0.03 | $0.08 |\n| Amortization of intangible assets | Approx. $0.26 | |\n| Asset impairment, restructuring and other special charges | $0.03 | $0.02 |\n| Other Expense, Net | $0.01 | $0.01 |\n| Subtotal | $0.30 | $0.29 |\n| Tax impact of adjustments | $(0.03) | $(0.03) |\n| Total adjustments to EPS | $0.27 | $0.26 |\n| Adjusted earnings per share (1) | $0.29 | $0.34 |",
    "footnotes": [
      "Numbers may not add due to rounding."
    ],
    "units": "",
    "page": 20,
    "bbox": [
      22.5,
      105.9,
      577.6,
      257.3
    ],
    "som_region": [
      0.03676470588235294,
      0.6750977641404278,
      0.9438121521395016,
      0.8662755176274464
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 97.09,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  },
  {
    "title": "First Quarter 2025 Guidance",
    "subtitle": "",
    "markdown": "| | First Quarter 2025 Guidance |\n| --- | --- |\n| Reported net income | $13 to $41 |\n| Net interest expense | Approx. $45 |\n| Income tax expense (benefit) | $0 to $(3) |\n| Depreciation and amortization | Approx. $160 |\n| EBITDA | $219 to $244 |\n| Non-GAAP adjustments |  |\n| Asset impairment, restructuring and other special charges | Approx. $15 |\n| Other Expense, Net | Approx. $5 |\n| Adjusted EBITDA | $240 to $260 |\n| Adjusted EBITDA margin | 21.0% to 22.2% |",
    "footnotes": [
      "Numbers may not add due to rounding."
    ],
    "units": "$ millions",
    "page": 22,
    "bbox": [
      22.5,
      535.6,
      576.0,
      712.6
    ],
    "som_region": [
      0.03676470588235294,
      0.10031308068169487,
      0.9411089529398999,
      0.32368775570031366
    ],
    "flavor": "stream",
    "kind": "text_table",
    "source": ".cache/s3/qubera-docs/daloopa/116212765/116212765.pdf",
    "camelot_accuracy": 100.0,
    "classifier_decision": null,
    "llm_corrected": true,
    "extraction_record": null
  }
]